Related Experiment Video

Updated: Aug 23, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report

Linlin Zhang1, Ping Xiao1, Fanlu Meng1

  • 1Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.

Current Oncology (Toronto, Ont.)
|October 27, 2022
PubMed

Insights

A rare STRN-ALK fusion in non-small cell lung cancer (NSCLC) was effectively treated with ensartinib, even with brain metastasis. This case highlights ensartinib as a potential therapy for NSCLC patients with this specific genetic alteration.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) harbors various genetic alterations, including Anaplastic Lymphoma Kinase (ALK) rearrangements.
  • STRN-ALK fusion is a rare subtype of ALK rearrangement with limited clinical data.
  • Targeted therapies are crucial for managing NSCLC with specific driver mutations.

Observation:

  • A patient with lung adenocarcinoma presented with brain metastasis.
  • Genetic analysis revealed the presence of a STRN-ALK fusion.
  • The patient's condition showed a positive response to ensartinib treatment.

Findings:

  • Ensartinib demonstrated significant efficacy in a patient with metastatic lung adenocarcinoma harboring the STRN-ALK fusion.
  • The treatment led to a favorable clinical outcome despite the presence of brain metastases.
  • This case provides clinical evidence for the effectiveness of ensartinib against STRN-ALK fusion.

Implications:

  • This case report expands the understanding of STRN-ALK fusion in NSCLC.
  • It suggests ensartinib as a viable therapeutic option for NSCLC patients with STRN-ALK fusion.
  • Further research into STRN-ALK fusion and its targeted treatment is warranted.
Keywords:
STRN-ALK fusionbrain metastasisensartiniblung adenocarcinoma

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K